Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, and Repligen Corporation, a global life sciences company focused on bioprocessing technologies, ...
WALTHAM, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Sartorius and Repligen Corporation (NASDAQ:RGEN) today announced the launch of an integrated bioreactor system that incorporates Repligen XCell® ATF ...
Sartorius Stedim Biotech (SSB) said today it will integrate Repligen’s XCell™ ATF cell retention control technology into SSB’s BIOSTAT® STR large-scale single-use bioreactors to create novel perfusion ...
One-Time Therapeutics Player Bets Future on Working as Supplier to Bioprocess Companies Repligen, once a strongly focused therapeutics firm, has transformed itself into a bioprocess products company ...
Repligen reported third-quarter revenue of $24.7 million. That's better than Wall Street expected and represents a 25% year-over-year increase. CEO Tony Hunt said that this impressive growth stemmed ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
It's been an up-and-down year so far in 2016 for Repligen Corporation (NASDAQ: RGEN). Repligen's stock price is close to where it was in January despite plenty of big moves along the way.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results